— Titan Pharmaceuticals (NASDAQ: TTNP) reported Q3 2019 loss of $0.18 per share, vs. $0.21 expected.
— Revenues fell 47% to approx. $0.9 million, vs. $0.7 million expected.
— Product revenues totaled approx. $0.2 million.
— Grant revenues totaled approx. $0.8 million.
— R&D expenses amounted to approx. $1.6 million.
— TTNP shares gained 1% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
What to expect when J.M. Smucker (SJM) reports Q4 2023 earnings
Shares of the J.M. Smucker Co. (NYSE: SJM) were up over 1% on Friday. The stock has gained 20% over the past one year. The company is slated to report
LULU Earnings: Highlights of Lululemon Athletica’s Q1 2023 financial results
Athletic wear company Lululemon Athletica (NASDAQ: LULU) has reported a double-digit increase in earnings and revenues for the first quarter of 2023. The company also provided positive guidance for the
Five Below (FIVE) Earnings: 1Q23 Key Numbers
Five Below, Inc. (NASDAQ: FIVE) reported net sales of $726.2 million for the first quarter of 2023, up 13.5% from the same period a year ago. Comparable sales increased 2.7%. Net
